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Abstract: Hemophilia A is a rare X-linked bleeding disorder caused by lack or dysfunction of 
coagulation factor VIII (FVIII). Hemophilia A is treated with replacement therapy, but frequent 
injections of the missing FVIII often lead to the formation of inhibitory antibodies. Patients who 
develop high levels of inhibitors must be treated with bypassing agents such as activated FVII 
(FVIIa). Both FVIII and FVIIa have short half-lives and require multiple injections. Long-acting 
forms of these proteins would therefore reduce the frequency of injections, improve patient 
compliance and reduce complications. In this article we present a new platform technology 
that produces long-acting forms of FVIII and FVIIa and improves the efficacy of hemophilia 
treatment. This technology is based on the binding of proteins/peptides to the outer surface of 
PEGylated liposomes (PEGLip). Binding is dependent on an amino acid consensus sequence 
within the proteins and is highly specific. At the same time, binding is non-covalent and does 
not require any modification of the therapeutic agent or its production process. Association of 
proteins with PEGLip results in substantial enhancements in their pharmacodynamic properties 
following administration. These improvements seem to arise from the association of formulated 
proteins with platelets prior to induction of coagulation.
Keywords: PEGylated liposomes, therapeutic proteins, pharmacodynamics, factor VIII, 
factor VIIa
Introduction
Hemophilia
Hemophilia is an inherited bleeding disorder caused by the lack or dysfunction of 
coagulation factors VIII (FVIII) or IX (FIX). The genes for FVIII and FIX are located 
on the X chromosome, and the vast majority of individuals with hemophilia are males. 
Hemophilia A accounts for approximately 75%–80% of all hemophilia cases with a 
prevalence of approximately 1/10,000 in the male population, whereas the prevalence 
of hemophilia B is 1/30,000.1,2 The severity of the bleeding tendency is determined by 
the residual clotting factor activity. Approximately 40% of hemophilia patients have 
a severe form of the disease, defined as having less than 1% (0.01 IU/ml) of normal 
factor activity.3
Hemophilia patients experience spontaneous hemorrhages into the joints, particularly 
the weight bearing joints such as knees, ankles and hips. This bleeding is painful and leads 
to long term inflammation and deterioration of the joint, resulting in permanent deformi-
ties, misalignment and loss of mobility. This is the major complication of hemophilia.4,5 
Bleeding may also occur into the muscles, soft tissues and other organs.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Hemophilia therapy
Hemophilia is treated by supplying patients with the missing 
coagulation factor (FVIII or FIX). Replacement therapy may 
be provided on-demand (to stop a bleed) or prophylactically 
(to prevent bleeds). When treatment is provided on-demand, 
injections must be initiated at the first onset of symptoms so 
as to limit both the amount of bleeding and the extent of the 
resulting tissue damage.6 Prophylactic treatment has been 
shown to provide hemophilia patients with better overall 
care than on-demand treatment as it reduces the frequency 
of hemorrhages and slows the development of long term 
arthropathy.7 However, prophylactic treatment is more 
expensive than on-demand treatment and is not accessible 
to many patients.6
In this review, we focus on the treatment of hemophilia A, 
the most common form of the disease. The FVIII used to 
treat hemophilia A may be produced in mammalian cell lines 
genetically engineered to synthesize human FVIII (recombi-
nant FVIII, rFVIII) or may be purified from normal pooled 
plasma (plasma-derived FVIII, pdFVIII).8
FVIII is a large glycoprotein (2332 amino acids) that 
is synthesized as a 330 kDa precursor and undergoes mul-
tiple processing steps to yield a heterodimer composed of 
a light chain (80 kDa) and a heterogeneous heavy chain 
(90–210 kDa)9 FVIII circulates in the plasma as an inactive 
precursor, tightly complexed with von Willebrand factor 
(vWF). Upon initiation of coagulation, FVIII is activated by 
thrombin. It dissociates from vWF, interacts with negatively 
charged phospholipids on the surface of activated platelets, 
and acts as a cofactor for factor IXa in the activation of 
factor X.1 This in turn leads to the generation of substantial 
amounts of thrombin, the key enzyme in the coagulation 
cascade, and to the generation of a hemostatic plug.
The half-life of human FVIII is about 10–12 hours.10,11 
Effective prophylactic therapy therefore requires three 
weekly infusions of 20–40 IU/kg to maintain FVIII above 
levels at which spontaneous bleeding occurs.7 The need for 
frequent infusions reduces quality of life and may lead to 
problems with compliance and injection complications.12 
Central venous access devices are frequently required, espe-
cially in children, but these devices are plagued by recurrent 
infections and thrombosis.13
Development of inhibitors  
and acquired hemophilia
Replacement treatment is complicated by the emergence of 
antibodies that inhibit the activity of the injected protein.14 
Approximately 20%–40% of hemophilia A patients and 
2%–3% of hemophilia B patients develop inhibitors.15,16 
As expected, the more profound mutations resulting in the 
lack of circulating FVIII or FIX are associated with higher 
risk of inhibitor development.17 Neutralizing or inactivat-
ing autoantibodies to FVIII may also develop in patients 
without a history of coagulation factor deficiency. This 
condition, known as acquired hemophilia, affects 0.2–1 out 
of every million people per year.18 Despite the low incidence 
of acquired hemophilia, the disorder is often devastating 
and the costs of treatment are immense. There is therefore 
considerable interest in improving and optimizing existing 
treatment regimens.18,19
Bypassing agents
Treatment of hemophilia patients with inhibitors is based 
primarily on controlling or preventing acute hemorrhages 
and their sometimes life threatening complications. Patients 
with low inhibitor titers may be given high doses of factor 
concentrate. While some of the factor is neutralized by the 
inhibitors, enough remains in the circulation to induce hemo-
stasis. Patients with high inhibitor titers ($5 Bethasda units, 
BU) cannot be treated by replacement therapy because even 
high doses of coagulation factor are rapidly inactivated by 
the circulating antibodies.20 These patients must be treated 
with agents capable of inducing hemostasis independent of 
the presence of FVIII or FIX (bypassing agents). Two such 
agents are in widespread use: activated prothrombin com-
plex concentrate (aPCC, also known as factor eight inhibi-
tor bypass activity, FEIBA, Baxter AG, Vienna, Austria)21 
and recombinant activated factor VII (rFVIIa; NovoSeven, 
Novo Nordisk AS, Bagsværd, Denmark).15,22 rFVIIa, given 
at supraphysiological doses, has been approved in many 
countries for the treatment of bleeding episodes in patients 
with congenital hemophilia and inhibitors to FVIII or FIX 
and patients with acquired hemophilia.23 The half-life of 
FVIIa in the circulation is approximately 2.3 hours.24,25 In 
most patients, bleeding episodes are therefore brought under 
control by administering two or three doses of 90 µg/kg given 
at two hour intervals.26,27
The need for a long-acting therapy  
for hemophilia
A long-acting form of FVIII would provide extended protec-
tion against bleeding and reduce gaps in protection caused 
by drops in FVIII levels between injections. Therefore, fewer 
injections would be required, resulting in fewer injection 
related complications, and better quality of life. Several 
attempts have been made to generate long-acting forms of International Journal of Nanomedicine 2010:5
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Figure 1 A schematic diagram showing a PeGLip formulated coagulation factor vIII (FvIII) or activated factor vII (FvIIa). The protein is non-covalently bound to a 
polyethylene glycol moiety on the outer surface of a PeGylated liposome. Binding is mediated by an amino acid consensus sequence within the protein (boxed in red). The 
actual consensus sequences, locations within the proteins’ sequences and affinity constants (KD) for FvIII (two binding sites) and FvIIa are shown above.
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FVIII.28 These included mutagenesis of the FVIII molecule 
to increase its stability29–31 and direct PEGylation of the 
FVIII protein.32–35 Modifying a large and complex protein 
such as FVIII is a difficult undertaking, though. The integ-
rity of multiple active sites must be maintained and protein 
conformation must be preserved. Development of modified 
forms of FVIII is still in the preclinical stage and the safety 
and efficacy of these approaches has yet to be demonstrated 
in humans.28
There is also a clinical need for a more potent and long-
acting form of FVIIa. As in the case of FVIII, long-acting 
FVIIa would require fewer injections, would reduce injection 
associated complications, and would provide patients with 
better control of bleeding episodes with fewer dips in FVIIa 
levels. Several approaches have been employed in attempts 
to improve FVIIa. These include substitution of one or more 
amino acids within the protein,36 PEGylation,37 and fusion 
of FVIIa to albumin.38 These proteins showed promising 
results in-vitro and in-animal models, but as in the case of 
FVIII, the efficacy and safety of these approaches has yet to 
be demonstrated in humans.
PEGylated liposome (PEGLip) 
technology
Liposomes, artificial phospholipid vesicles, have proven to be 
useful in stabilizing drugs and improving their pharmacological 
properties. In most cases, liposomes are used to encapsulate the 
therapeutic agent (usually a small molecule drug).39 Modify-
ing the liposome surface with molecules such as polyethylene 
glycol prevents adsorption of plasma proteins to the liposome 
surface and interferes with recognition and uptake by the reti-
coloendothelial system (RES). This results in the generation of 
liposomes with a dramatically extended circulation time.40,41
PEGylated liposome (PEGLip) technology is a new 
approach to improving the pharmacodynamic properties 
of therapeutic proteins. Instead of encapsulating the drug, 
PEGylated liposomes are used as carriers with the protein 
bound non-covalently but with high specificity to the outer 
surface (Figure 1). Unlike approaches such as mutagenesis, 
direct PEGylation, or fusion to carrier proteins, PEGLip 
technology does not involve changes to a protein’s amino 
acid sequence and does not involve covalent attachment of 
stabilizing agents.
The PEGLip that we typically produce are composed of a 
97:3 molar ratio of 1-palmitoyl-2-oleoyl phosphatidylcholine 
(POPC) to 1,2 distearoyl-sn-glycero-3-phosphatidyletha-
nolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-
PEG 2000). The liposomes are prepared as follows. Lipids 
are dissolved in tert-butanol and lyophilized. The resulting dry 
lipid powder is resuspended to 110 mM lipid in 50 mM sodium 
citrate, pH 6.7 to form liposomes. The liposomes are then 
down-sized by extrusion through sequentially smaller polycar-
bonate filters until they reach a final diameter of 80–100 nm. 
The PEG molecules that extend outward from the liposome 
surface mediate binding of FVIII, FVIIa and other proteins 
to the liposome surface (Figure 1). As mentioned above, the 
PEG molecules also limit uptake of the liposomes by the RES, 
thereby extending half-life in the circulation.42–44
The binding of PEGLip to FVIII and FVIIa was demon-
strated in real time using surface plasmon resonance (SPR). 
The protein being assayed was bound to the surface of a chip 
and association of liposomes was measured as a liposome 
solution flowed over the chip. SPR measurements showed that 
PEGLip bind both recombinant and plasma-derived FVIII45,46 
as well as FVIIa.47 PEGLip also bind additional proteins 
such as recombinant human granulocyte   colony-stimulating International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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factor (G-CSF), granulocyte macrophage colony-stimulating 
factor (GM-CSF), and glucagon-like peptide 1 (GLP-1).48 
Affinity constants (KD ) for all of these interactions were 
in the low nM range (0.4–12 nM). All of the proteins that 
bind PEGLip share a consensus sequence of 8 amino acids 
(S/T–X–L/V–I/Q/S–S/T/Q–X–X–E) (Figure 1). A synthetic 
peptide derived from one of the two consensus sequences in 
FVIII (amino acids 1783–1796 of FVIII) also binds PEGLip 
with high affinity (KD of 2.3 nM). PEGLip do not bind sev-
eral proteins that lack the consensus sequence, highlighting 
its significance for binding. These proteins include human 
serum albumin (HSA), human IgG, insulin, interferon 
alpha 2a, interferon alpha 2b, human growth hormone, and 
erythropoietin.48 Together, our data show that the consensus 
sequence is sufficient to mediate the binding of the proteins/
peptides to PEGLip.
We also sought to identify the molecules or structure on 
PEGLip responsible for protein/peptide binding. We found 
that non-PEGylated POPC liposomes do not bind FVIII,45,46 
FVIIa,47 or the FVIII-derived synthetic peptide.48 Analy-
ses performed with liposomes composed of various types 
of lipids and lipid polymers revealed that the interaction 
between PEGLip and proteins is mediated primarily by the 
PEG molecule and the carbamate group adjacent to the PEG 
molecule within DSPE-PEG 2000.48 When PEG molecules 
were not present on the liposome surface (as in the case of 
POPC liposomes) no binding occurred. Likewise, when 
proteins lacking the consensus sequence were assayed, no 
binding was observed. Liposome-protein binding is therefore 
highly specific.
Formulation of FVIII and FVIIa  
with PEGLip
Formulation of a protein with PEGylated liposomes is very 
straightforward. The lyophilized protein powder of FVIII 
or FVIIa is simply reconstituted in liposome solution and 
allowed to fully dissolve. Even large and sensitive proteins 
such as FVIII may be formulated without any change in 
the production process or the purification procedure.45–47,49 
  Formulation is very gentle and it does not involve any cova-
lent modification of the protein. The protein’s native structure 
is not changed, and the likelihood of antibody production 
does not increase. The protein is fully active immediately 
after formulation45–47 and it is free to interact with its normal 
binding partners.45 Administration to patients remains for 
the most part unchanged, though dosage and frequency of 
injections may need to be adjusted to account for extended 
therapeutic activity.
PeGLip-formulated FvIII
FVIII binds PEGLip specifically and with high affinity (two 
binding sites, KD of 4.5 and 1.9 nM), but this interaction 
does not alter FVIII activity, as shown by maintenance of full 
activity after formulation.45,46 The association of FVIII with 
PEGLip does not affect the FVIII protein’s structure. This was 
demonstrated by binding of several anti-FVIII antibodies to 
FVIII following PEGLip formulation45 Moreover, PEGLip 
formulation allows FVIII to interact with its natural binding 
partners. This was shown by in-vitro binding of PEGLip- 
formulated FVIII to vWF.45 Thus binding of PEGLip to FVIII 
does not change the protein’s biological properties.
PEGLip formulation of both recombinant and plasma– 
derived forms of FVIII extends hemostatic efficacy in vivo. 
This was demonstrated by better survival of hemophilic mice 
following tail-vein transection. Standard FVIII, PEGLip-
FVIII, or saline were administered to hemophilic mice 
24 hours prior to transection of the left lateral tail vein. Mice 
that received PEGLip-FVIII bled less and survived signifi-
cantly longer (P , 0.05) than mice that received standard 
FVIII or saline (Figure 2A).45,46 This significantly increased 
survival of tail-vein transected hemophilic mice following 
the injection of PEGip formulated recombinant FVIII was 
also demonstrated by others.50 The increased survival rate 
was dependent on the pre-formation of a complex of FVIII 
and PEGLip. Clotting times of whole blood samples from 
hemophilic mice injected with PEGLip-FVIII were much 
shorter than the clotting times of blood samples from mice 
injected with free FVIII. This faster clotting was detected 
shortly after injection and at various time points up to 
72 hours post injection.50
PEGLip-FVIII provides human subjects with extended 
protection from bleeding.49 Several clinical trials tested the 
safety and the efficacy of PEGLip rFVIII (also referred to as 
BAY 79-4980).51 A single arm, subject blinded clinical trial 
was performed to assess the efficacy and safety of two levels 
of FVIII (25 or 35 IU/kg) with a fixed dose of liposomes 
(22 mg lipids/kg). Twenty-three severe hemophilia A patients 
were treated in three study segments. Standard FVIII was 
administered in the first study segment whereas PEGLip-FVIII 
was provided in the second and third segments. Segments were 
separated by 4-day washout periods and each prophylactic 
infusion was administered while subjects were in a non-
bleeding state. As a measure of efficacy, the time between 
each prophylactic infusion and the next spontaneous bleed 
was recorded. Prophylactic treatment with PEGLip-FVIII 
nearly doubled the length of time subjects were protected 
from spontaneous bleeding (Figure 2B). A single   prophylactic International Journal of Nanomedicine 2010:5
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Figure 2 Efficacy of PEGLip-formulated FVIII in preclinical experiments and a clinical trial. A) Efficacy in an animal model. Hemophilic mice were injected into the tail vein with 
PEGLip-formulated FVIII, standard FVIII (both 0.1 IU/mouse), or saline. Twenty-four hours after injection, the left lateral tail vein of each mouse was cut and survival was scored. 
B) Efficacy in a clinical trial. Hemophilia A patients were given 25 IU/kg or 35 IU/kg of standard or PEGLip-formulated FVIII and the time between the prophylactic infusion and 
the next spontaneous bleed was recorded. The number of bleeding-free days following each treatment is shown. Results are average ± SeM.
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injection of 25 IU/kg PEGLip-FVIII resulted in a mean 
  bleed-free   interval of 10.9 days   compared to 5.9 days with 
standard FVIII. Similarly, injection of 35 IU/kg PEGLip-FVIII 
resulted in a mean bleed-free interval of 13.3 days   compared to 
7.2 days with standard FVIII. This difference was significant 
(P , 0.05) for both dose levels (Figure 2B).49
A subsequent randomized, subject blinded, four-way 
crossover study involving 16 hemophilia A patients   evaluated 
the efficacy and safety of prophylactic infusions of   various 
PEGLip doses (4.2, 12.6, or 22.1 mg/kg) with a fixed FVIII 
dose (35 IU/kg). Mean number of bleeding-free days after 
each infusion increased from 7.8 days for 35 IU/ml of 
standard FVIII to 8.7, 10.8, and 10.9 days for 35 IU/ml of 
FVIII formulated in 4.2, 12.6, and 22.1 mg/kg of PEGLip, 
respectively.52 The study showed a dose response to PEGLip 
that reached saturation at the highest dose level.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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An additional study tested the safety of PEGLip-FVIII 
and compared its pharmacokinetic profile to that of standard 
FVIII.53 In this randomized double-blind study, 26 severe 
hemophilia A patients received a single injection of standard 
FVIII (35 IU/kg) followed by 12 observation days and a 4-day 
Washout period. Patients then received a single injection of 
PEGLip-FVIII (35 IU/kg FVIII, 13 or 22 mg/kg PEGLip) fol-
lowed once again by 12 days of observation. Pharmacokinetic 
(PK) analysis based on samples taken from patients during the 
trial showed no significant difference between standard FVIII 
and PEGLip-FVIII. This suggests that the increased protection 
from bleeding observed with PEGLip-FVIII did not result from 
a simple prolongation of FVIII half-life in the blood stream.
Safety and tolerability of PEGLip-FVIII were assessed 
in another clinical trial involving 18 severe hemophilia A 
patients. This study was directed primarily at determining the 
optimal infusion rate for PEGLip-FVIII. The study showed 
that PEGLip-FVIII may be administered at an infusion rate 
similar to that of standard FVIII.54
In all four of the studies described above, no production 
of inhibitory antibodies was detected, and no serious adverse 
events were reported. However, a few subjects experienced 
increased breathing frequency and flushing.53,54 At the first 
sign of symptoms, infusions were stopped and the patients 
recovered fully without further medical intervention. This 
type of hypersensitivity reaction is known as complement 
activation related pseudoallergy (CARPA) and has been 
described following administration of radiocontrast media, 
liposomal drugs, and micellar solvents. Unlike IgE medi-
ated reactions, CARPA reactions arise at first treatment and 
become milder or disappear upon repeated exposure.54,55
The combined results of the phase I and II clinical studies 
described above show that PEGLip-FVIII is well tolerated 
and provides extended protection from bleeding following 
prophylactic treatment.
PeGLip-formulated FvIIa
PEGLip formulation is desirable for FVIIa because this thera-
peutic protein has an extremely short half-life in the circula-
tion (approximately 2.3 hours).24,25 In most patients treated 
with FVIIa, effective hemostasis is achieved only after two or 
three doses of 90 µg/kg26,27 given at two hour intervals.
SPR analyses showed that PEGLip bind specifically to 
FVIIa. As in the case of FVIII, binding of liposomes to FVIIa 
was dependant on the presence of the DSPE-PEG lipopolymer. 
POPC liposomes lacking DSPE-PEG bound FVIIa to a much 
lower level than PEGLip. Kinetic analysis of the PEGLip-
FVIIa interaction indicated that the PEGLip bind to FVIIa 
with an affinity (KD) of 0.4 nM.47 Formulation of FVIIa with 
PEGLip did not affect its in vitro activity.47 Most importantly, 
formulation of FVIIa with PEGLip improved survival of hemo-
philic mice following tail vein transection. Hemophilic mice 
were injected with standard FVIIa, PEGLip-FVIIa, or saline. 
Fifteen minutes after injection, tail veins were transected and 
survival was scored up to 24 hours. We found that mice injected 
with PEGLip-FVIIa survived significantly longer (P , 0.05) 
than mice injected with standard FVIIa (Figure 3A).
The safety and efficacy of PEGLip-FVIIa were tested in 
humans in an open label, exploratory, cross over, phase I/II 
clinical study in six adult subjects with severe hemophilia 
A and inhibitory FVIII antibodies.56 Each subject received 
two infusions: one infusion of 90 µg/kg standard FVIIa and 
one infusion of 90 µg/kg PEGLip-formulated FVIIa. The 
two infusions were separated by a 10-day washout period. 
Injection volume was kept constant while injection order was 
randomized. Blood samples were collected from patients at 
various time points both before and after each infusion of 
FVIIa or PEGLip-FVIIa. Whole blood samples were then 
analyzed by rotational thrombelastography, a method record-
ing the kinetics of clot formation and the firmness of the clots. 
PEGLip-formulated FVIIa produced significantly (P , 0.05) 
shorter clotting times and higher clot firmness than standard 
FVIIa up to 5 hours post injection. Clotting time of standard 
FVIIa 30 min post injection was the same as clotting time of 
PEGLip-FVIIa 2 hours post injection. Clotting time of standard 
FVIIa 1 hour post injection was the same as clotting time of 
PEGLip-FVIIa 3.2 hours post injection (Figure 3B). Maximal 
clot firmness induced by standard FVIIa 0.5 hour post injection 
was as high as that induced by PEGLip-FVIIa ∼2.7 hours post 
injection. Thrombin generation assays showed that thrombin 
was produced faster and more efficiently following infusion 
of PEGLip-FVIIa than following infusion of standard FVIIa. 
No significant differences were detected between the PK of 
PEGLip-FVIIa and standard FVIIa.
One of the subjects in the trial experienced transient 
hyperemia, an increase in blood pressure and anxiety during 
the infusion of the first 1 mL of PEGLip-FVIIa. This non-IgE 
mediated reaction (CARPA) is associated with PEGLip.55 and 
is not related to FVIIa. The reaction subsided within one hour. 
In all other subjects, PEGLip-FVIIa was well tolerated and 
there were no serious adverse events nor were there any sig-
nificant changes in vital signs, clinical chemistry or hemato-
logical parameters. Measurements of coagulation parameters 
indicated that there was no increase in thrombotic risk.
An analysis of the results of the clinical trial indicates 
that PEGLip-FVIIa provides about two more “efficacy hours” International Journal of Nanomedicine 2010:5
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Figure 3 Efficacy of PEGLip-formulated FVIIa in preclinical experiments and a clinical trial. A) Efficacy in an animal model. Hemophilic mice were injected with PEGLip-FVIIa, 
standard FvIIa (both 10 µg/mouse), or saline. The right and left lateral tail veins of each mouse were cut 15 min post injection and survival was scored. B) Efficacy in a clinical trial. 
Hemophilia patients with inhibitors were injected prophylactically with 90 µg/kg FvIIa ( ) or 90 µg/kg PeGLip-FvIIa (•). Total clotting times at 0.5–5 hours post injection were 
analyzed by thrombelastography. No clotting (total clotting time .3600 sec) was detected in any of the subjects in the hour preceding infusions. The dashed lines compare clotting 
times induced by PeGLip-FvIIa to those induced by standard FvIIa. Results are average ± SeM (n = 6). *P , 0.05, **P = 0.08 (FvIIa vs PeGLip-FvIIa, paired t-test).
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than standard FVIIa. In treatment of bleeding episodes in 
hemophilia patients with inhibitors, one 90 µg/kg dose of 
PEGLip-FVIIa may be roughly equivalent to two infusions 
of standard FVIIa given at 2-hour intervals.
Mechanism of action
In preclinical models, formulation of FVIII and FVIIa 
with PEGLip improved pharmacokinetic properties in vivo 
and increased circulation half-life.45–47 However, phase I 
clinical experiments showed that there was no difference 
between the pharmacokinetic behavior of standard FVIII and 
PEGLip-formulated FVIII53 and between standard FVIIa and 
PEGLip-formulated FVIIa.56 This suggests that extension of 
  circulation half-life is not the primary mechanism responsible 
for increased hemostatic efficacy.
Extensive in vitro experiments measuring clot forma-
tion and lysis by rotational thrombelastography, indicate that 
platelets must be present in order for PEGLip formulation to International Journal of Nanomedicine 2010:5
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Figure 4 Mechanism of action of PeGLip-formulated FvIII and FvIIa. 
1.  Formulation of FvIII or FvIIa with PeGLip leads to non-covalent binding of the protein to the outer surface of the PeGylated liposomes. 
2.  The liposomes are then injected into the bloodstream where they associate with non-activated platelets. 
3.   when injury occurs, platelets are recruited to the wound where they adhere to the damaged vessel wall. They carry FVIII and FVIIa with them. Platelet activation and 
initiation of the coagulation cascade occur simultaneously. 
4.   Coagulation complexes form on the surface of the activated platelets. Since FvIII and FvIIa are already present on the platelets prior to activation, the coagulation cascade 
is more efficient. Clots form faster and the clots are more stable.
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improve the hemostatic properties of FVIII and FVIIa.47,57 
When PEGLip-FVIII and PEGLip-FVIIa were added to severe 
hemophilic whole blood or platelet rich plasma, clots formed 
much faster than when similar concentrations of standard FVIII 
and FVIIa were used. Clots were also firmer and more resistant 
to fibrinolysis. Similarly, ex-vivo rotational thrombelastometry 
experiments in whole blood drawn from hemophilic mice indi-
cated that clotting times were much faster in mice injected with 
PEGLip-FVIII rather than with free FVIII.50 Such improve-
ments in kinetics, clot firmness, and resistance to fibrinolysis 
depended on platelets as they were not observed when experi-
ments were performed in platelet poor plasma.57
In order to gain a deeper understanding of the mechanisms 
responsible for these improvements in efficacy, we tested 
whether PEGLip themselves bind platelets. Flow cytometry 
analysis indicated that fluorescent PEGLip associate with 
platelets in-vitro in a dose related manner. This associa-
tion was further confirmed in-vivo following the injection 
of   fluorescent PEGLip into hemophilic mice.57 Interactions 
between liposomes of various compositions, including PEG 
liposomes, and blood cells have been reported previously by 
others.50,58
Having shown that PEGLip bind FVIII and FVIIa45,47 
and that PEGLip bind platelets, we next tested whether 
PEGLip are capable of delivering proteins to platelets. 
Fluorescently labeled FVIII and FVIIa were formulated with 
non-fluorescent PEGLip and shown by flow cytometry to 
bind human platelets in-vitro. These results were also found 
in-vivo as PEGLip-formulated fluorescent proteins interacted 
with the platelets of hemophilic mice following injection.57 
Fluorescently labeled human serum albumin (HSA), which 
does not bind to PEGLip, did not show increased binding to 
platelets following formulation with PEGLip. This indicates 
that PEGLip-mediated association of proteins with platelets 
is dependent on prior binding of the proteins to PEGLip.
The combined results indicate the following mechanism 
(Figure 4): Formulation of FVIII or FVIIa with PEGLip leads 
to non-covalent binding of the protein to the outer surface of International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
589
PeGylated liposomes mediated drug delivery in hemophilia
the PEGylated liposomes. After injection of the formulated 
proteins to the bloodstream the liposomes associate with 
non-activated platelets and a complex of platelet-PEGLip- 
protein (FVIII/FVIIa) is formed in-vivo. Following injury, 
platelets are recruited to sites of injury where they adhere to 
the damaged vessel wall. Due to their prior association with 
PEGLip, they carry FVIII and FVIIa with them. Platelets are 
activated at the wound site and coagulation complexes form 
on the surface of the activated platelets. Since FVIII and 
FVIIa are already present on the platelets prior to activation, 
the coagulation cascade is more efficient. Clots form faster 
and the clots are more stable.
The association of PEGLip-FVIII or PEGLip-FVIIa with 
platelets may also lead to increased concentration of FVIII 
or FVIIa at the wound site, even when the overall concentra-
tion of FVIII or FVIIa in the circulation is low. Accordingly, 
expression of FVIII in platelets was shown to be effective 
at inducing hemostasis even when FVIII protein expression 
levels did not exceed 1% of normal levels. This was probably 
due to recruitment of platelets to the sites of injury and local 
release of FVIII from activated platelets at wound sites.59
Summary
PEGLip technology improves the pharmacodynamic prop-
erties of both coagulation factors VIII and VIIa. This was 
demonstrated in preclinical experiments and in five differ-
ent clinical trials with both FVIII and FVIIa. The combined 
results indicate that PEGLip-FVIII prevents bleeding for a 
significantly longer period than standard FVIII, and that one 
dose of PEGLip-FVIIa may be roughly equivalent to two 
infusions of standard FVIIa given at 2 hour intervals when 
treating a bleed in hemophilia patients with inhibitors.
Of the approaches currently available to generate long-
acting forms of FVIII and FVIIa, PEGLip formulation has 
the advantage of being the only approach that has been tested 
extensively in clinical trials. PEGLip-FVIII and PEGLip-
FVIIa have been shown to be safe in trials involving more 
than 90 hemophilia patients. In general, treatments with 
PEGLip-formulated FVIII and FVIIa were well tolerated.
One of the most problematic complications of hemo-
philia treatment is the induction of inhibitory antibodies. 
PEGLip formulation does not change the structure of FVIII 
and FVIIa. It thereby avoids one of the biggest obstacles to 
producing improved coagulation factors: changes in structure 
that induce antibody formation. Because of the large size 
and complexity of the FVIII protein and the sensitivity of 
hemophilia A patients to even small changes in the protein,60,61 
FVIII can be considered a worst case scenario for increased 
immunogenicity. Extensive experience with PEGLip-FVIII 
in several clinical studies has shown no increase in antibody 
generation. PEGLip formulation thus avoids one of the major 
pitfalls of the drug development process.49,52,53
PEGLip-FVIII/FVIIa are well tolerated and suitable for 
long-term treatment of hemophilia. This was demonstrated 
in toxicology studies, which included injecting high doses 
of PEGLip-FVIII and PEGip-FVIIa into rats and rabbits 
(acute toxicology) and repeated injections (up to nine months 
of weekly injections) of PEGLip into rats and rabbits.45 
PEGylated liposomes were also shown to be non-toxic in 
mice and dogs.62
In the years to come, we expect PEGLip-FVIII and PEG-
Lip-FVIIa to become an attractive treatment for hemophilia 
A patients and hemophilia patients with inhibitors.
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